BRIEF-Elicio Therapeutics Announces Positive Recommendation By Idmc To Continue Eli-002 7P Randomized Phase 2 Study In Pancreatic Cancer Without Modifications To Final Analysis

Reuters
Aug 05
BRIEF-<a href="https://laohu8.com/S/ELTX">Elicio Therapeutics</a> Announces Positive Recommendation By Idmc To Continue Eli-002 7P Randomized Phase 2 Study In Pancreatic Cancer Without Modifications To Final Analysis

Elicio Therapeutics Inc ELTX.O:

  • ELICIO THERAPEUTICS ANNOUNCES POSITIVE RECOMMENDATION BY IDMC TO CONTINUE ELI-002 7P RANDOMIZED PHASE 2 STUDY IN PANCREATIC CANCER WITHOUT MODIFICATIONS TO FINAL ANALYSIS

  • ELICIO THERAPEUTICS INC - FINAL DFS ANALYSIS EXPECTED IN Q4 2025

  • ELICIO THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q1 2026

  • ELICIO THERAPEUTICS INC - IDMC CONFIRMS SAFETY PROFILE OF ELI-002 7P

Source text: ID:nGNX8mRDWT

Further company coverage: ELTX.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10